|
Matthew Silverman Memorial Foundation
|
Beverly Hills, CA
|
$50K
|
General purpose
|
2023
|
|
Translational Genomics Research Institute Foundation
|
Phoenix, AZ
|
$3.0M
|
Establishment of the robert & Lynda Carter Altman Family Research Fund with tgen and its affiliate, city of hope, to facilitate research efforts in two complementary areas specifically designed for rapid improvement of patient outcomes who suffer from mpn/saml. One research project, the therapeutic research project, to be conducted by the city of hope will comprehensively test and scale up the manufacture of the drug denominated as mir-142. This "mimetic" drug simulates (replaces) the action of a normal signal that is missing in mpn/saml patients.
|
2023
|
|
Translational Genomics Research Institute Foundation
|
Phoenix, AZ
|
$2.7M
|
Establishment of the robert & Lynda Carter Altman Family Research Fund with tgen and its affiliate, city of hope, to facilitate research efforts in two complementary areas specifically designed for rapid improvement of patient outcomes who suffer from mpn/saml. One research project, the diagnostic research project, is to be conducted by tgen to develop two diagnostic tests. The fIRSt diagnostic research project is to identify the most sensitive test for the transition from mpn to saml. The second diagnostic research project is to develop and deploy an ultra-rapid whole genomic sequencing test to identify drug treatment options for patients who have transitioned from mpn to saml.
|
2023
|
|
Smithsonian Institution
|
Washington, DC
|
$200K
|
General purpose
|
2023
|
|
Translational Genomics Research Institute Foundation
|
Phoenix, AZ
|
$1.3M
|
Establishment of the robert & Lynda Carter Altman Family Research Fund with tgen and its affiliate, city of hope, to facilitate research efforts in two complementary areas specifically designed for rapid improvement of patient outcomes who suffer from mpn/saml. One research project, the therapeutic research project, to be conducted by the city of hope will comprehensively test and scale up the manufacture of the drug denominated as mir-142. This "mimetic" drug simulates (replaces) the action of a normal signal that is missing in mpn/saml patients.
|
2022
|
|
Translational Genomics Research Institute Foundation
|
Phoenix, AZ
|
$3.1M
|
Establishment of the robert & Lynda Carter Altman Family Research Fund with tgen and its affiliate, city of hope, to facilitate research efforts in two complementary areas specifically designed for rapid improvement of patient outcomes who suffer from mpn/saml. One research project, the diagnostic research project, is to be conducted by tgen to develop two diagnostic tests. The fIRSt diagnostic research project is to identify the most sensitive test for the transition from mpn to saml. The second diagnostic research project is to develop and deploy an ultra-rapid whole genomic sequencing test to identify drug treatment options for patients who have transitioned from mpn to saml.
|
2022
|
|
Translational Genomics Research Institute Foundation
|
Phoenix, AZ
|
$4.3M
|
General purpose
|
2022
|
|
Smithsonian Institution
|
Washington, DC
|
$200K
|
General purpose
|
2022
|